Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Single-cell transcriptomic insights into venetoclax response and resistance in secondary AML evolving from MDS

View Full Paper
Ask AI
Bookmark
Share

Authors

SPSilvia ParkJJJinho JangJLJaewoong Lee

Discussion

Loading...

Member takes

Overview

This analysis demonstrates altered immune dysregulation and HSPC pathways in venetoclax-treated AML, suggesting new therapeutic targets.

Key Points

  • Altering HSPC pathways may enhance response to venetoclax in secondary AML.
  • Hematopoietic stem/progenitor cells exhibited changes linked to venetoclax resistance mechanisms.
  • Single-cell RNA sequencing was applied to analyze 279,211 bone marrow cells collected from treatment samples.
  • Immune dysregulation in the bone marrow microenvironment may hinder effective therapy, indicating a need for dual-target strategies.

Cite This Study

Park et al. (2025) studied this question.

synapsesocial.com/papers/69362f4b4fa91c937236d795https://doi.org/10.1182/blood-2025-2061
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Phenotypic heterogeneity and remodeling drive resistance to venetoclax treatment in acute myeloid leukemia2025 · 1 citations
  2. 2Single-cell insights into acute myeloid leukemia treated with venetoclax-based therapy2025
  3. 3Mechanistic dissection of venetoclax sensitivity in AML through single-molecule BCL2 protein complex profiling and mutation-specific apoptotic rewiring2025 · 1 citations
  4. 4Dietary serine restriction increases venetoclax efficacy in Acute Myeloid Leukemia2025
  5. 5Does the Timing of Response Impact the Outcome of Relapsed/Refractory Acute Myeloid Leukemia Treated with Venetoclax in Combination with Hypomethylating Agents? A Proof of Concept from a Monocentric Observational Study2025 · 3 citations